← back to search

Kyle Lapidus

Laidlaw College · NZ
Area of research
Pharmacology · Biological Psychiatry
Research interest
Research interests include Treatment of Major Depression, Tryptophan and brain disorders, Obsessive-Compulsive Spectrum Disorders, and Cancer Cells and Metastasis.
h-index
25
citations
5,851
works
62
NIH funding
primary concept
email

Recent publications

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial
The British Journal of Psychiatry 2023cited by 64position: middledoi
Efficacy and Safety of Repeated Subcutaneous Ketamine Injections for Treatment Resistant Depression - The KADS Study: A Randomised, Double-Blind, Comparator-Controlled Trial
SSRN Electronic Journal 2022cited by 1position: middledoi
Deep Transcranial Magnetic Stimulation Combined With Brief Exposure for Posttraumatic Stress Disorder: A Prospective Multisite Randomized Trial
Biological Psychiatry 2021cited by 90position: middledoi
The Significance of the Default Mode Network (DMN) in Neurological and Neuropsychiatric Disorders: A Review.
PubMed 2016cited by 310position: last
Elevated prefrontal cortex GABA in patients with major depressive disorder after TMS treatment measured with proton magnetic resonance spectroscopy
Journal of Psychiatry and Neuroscience 2016cited by 153position: middledoi
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial
Psychological Medicine 2015cited by 294position: middledoi
Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis
The International Journal of Neuropsychopharmacology 2015cited by 229position: middledoi
Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress
Proceedings of the National Academy of Sciences 2014cited by 698position: middledoi
Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder
JAMA Psychiatry 2014cited by 608position: middledoi
A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
Biological Psychiatry 2014cited by 479position: firstdoi
Ketamine for Treatment-Resistant Unipolar Depression
CNS Drugs 2012cited by 240position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

James W. Murrough · Center for Anxiety and Depression5 papers (2012–2015)Dennis S. Charney · Riverkeeper3 papers (2014–2015)Andrew M. Perez · University of Central Florida3 papers (2014–2015)Dan V. Iosifescu · Psychiatric Medical Center3 papers (2014–2015)Jess W. Brallier · Memorial Sloan Kettering Cancer Center2 papers (2014–2015)Laili Soleimani · Alzheimer’s Disease Neuroimaging Initiative2 papers (2014–2015)Michael K. Parides · Hospital for Special Surgery2 papers (2014–2014)Adriana Feder · Icahn School of Medicine at Mount Sinai2 papers (2014–2014)Martin J. Carney · Tulane University1 papers (2016–2016) · 1 papers (2021–2021) · 1 papers (2014–2014)Herbert E. Ward · University of Florida1 papers (2021–2021) · 1 papers (2016–2016)Sandeep Vaishnavi · Manipal Academy of Higher Education1 papers (2021–2021)Vaishnav Krishnan · Baylor College of Medicine1 papers (2014–2014)Joseph Zohar · Sheba Medical Center1 papers (2021–2021)Daniel M. Blumberger · Centre for Addiction and Mental Health1 papers (2021–2021)Colleen Loo · Black Dog Institute1 papers (2015–2015)Zafiris J. Daskalakis · Centre for Addiction and Mental Health1 papers (2021–2021)Mark S. George · Veterans Health Administration1 papers (2021–2021)